Latest Breaking News On - Evan dellon - Page 2 : comparemela.com

How new drug approvals are reshaping treatment for eosinophilic esophagitis

How new drug approvals are reshaping treatment for eosinophilic esophagitis
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Evan dellonSabina mirChristopher leeChildren research instituteSchool of medicineDivision of gastroenterologyTakeda pharmaceuticalsClinical gastroenterologyResearch institute

Eohilia Gets FDA Approval for Swallowing Disorder Eosinophilic Esophagitis

Eohilia is the first FDA-approved treatment specifically for eosinophilic esophagitis, a rare inflammatory disease of the esophagus.

United statesErin syversonEvan dellonUniversity of north carolinaDrug administrationBrandon monkBusiness unitEsophageal diseasesNorth carolinaEosinophilic gastrointestinal disease programBoston children

Dupilumab for EoE: How Is it Improving Treatment?

The drug was a boon for many patients, mainly those with moderate to severe disease, but cost and insurance approvals posed challenges.

University of north carolinaNorth carolinaUnited statesNew yorkRegeneron sanofiPhilip katzEvan dellonDrug administrationUniversity of north carolina at chapel hillMajor advanceWeill cornell medicineNew york cityMedscape medicalNew england journalEsophageal diseasesChapel hill

Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Evan dellonDupilumab dupixentJulie khlevnerDrug administrationUniversity of north carolina chapel hillContemporary pediatricEsophageal diseasesNorth carolina chapel hillPediatric gastrointestinal motility centerColumbia university medical centerInflammatory bowel diseaseEosinophilic esophagitisUlcerative colitis

FDA Grants Orphan Drug Designation to 1104, First-In-Class Peptide for Eosinophilic Esophagitis

The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE.

United statesEvan dellonRevolo biotherapeuticsUniversity of north carolina chapel hillOrphan drug designationAdjunct professorNorth carolina chapel hillPrincipal investigatorWoody bryanChief executive officerFirst in class peptidePotential treatmentDev landscapeActive eosinophilic